Evidence map›Paper›PMID 25974703›Full record

GuidelineClinical pharmacology and therapeutics2015

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake Inhibitors.

J K Hicks, J R Bishop, K Sangkuhl, D J Müller, Y Ji, S G Leckband, J S Leeder, R L Graham, D L Chiulli, A LLerena and 7 more

4 registry-linked trialsOpen access · bronzeAbstract readPractice Guideline
PubMed Full text at PMC Publisher
In one paragraph

Guideline in Clinical pharmacology and therapeutics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 4 registered trials, which are not on this map. Cited by 480 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
480citing papers in PubMed, 8 pooled it
84.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02625155 phase4unknown statusnot on this map

Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens: SPHERE

TypeinterventionalSponsorInSource DiagnosticsRan2015Enrolled14,000ConditionsTarget Drug-related Adverse EventsArmsUrine diagnostic testing as SOC, drug regimen changes per SOC, Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results
NCT02770339 completednot on this mapstarted 2016, after this paper: background citation

Pharmacogenomic Profiling of Pediatric Patients on Psychotropic Medications in an Emergency Department

TypeobservationalSponsorUniversity of Alabama at BirminghamRan2016 to 2017Enrolled100ConditionsMental Disorders, Metabolism Medication Toxicity, Pediatric Disorder
NCT04727827 nacompletednot on this mapstarted 2021, after this paper: background citation

A Prospective Interventional Trial of Pharmacogenomic-Guided Supportive Care in Hematopoietic Cell Transplantation

TypeinterventionalSponsorWake Forest University Health SciencesRan2021 to 2023Enrolled110ConditionsHematopoietic Cell Transplantation, OncologyArmsPharmacogenomic-guided supportive care
NCT05091879 nacompletednot on this mapstarted 2023, after this paper: background citation

Implementation and Evaluation of Preemptive Pharmacogenomics Testing in an Aging Population

TypeinterventionalSponsorGeisinger ClinicRan2023 to 2026Enrolled66ConditionsPolypharmacy, Pharmacogenomic TestingArmsMultigene pharmacogenomics test
3 · Its place in the literature

Who cites it

480 citing papers in PubMed, 8 syntheses or guidelines pooled it, 958 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Guideline
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. The role ofExpert review of clinical pharmacology · 2022
    Pooled it
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

420 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 13 institutions in 4 countries.

J K HicksDepartment of Pharmacy, Cleveland Clinic, Cleveland, Ohio, USA; Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA; and Department of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio, USA.
J R BishopUniversity of Minnesota College of Pharmacy, Department of Experimental and Clinical Pharmacology, Minneapolis, Minnesota, USA.
K SangkuhlDepartment of Genetics, Stanford University, Stanford, California, USA.
D J MüllerCampbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada; Department of Psychiatry, University of Toronto, Toronto, Ontario, Canada.
Y JiDepartment of Laboratory Medicine and Pathology, Division of Laboratory Genetics, Mayo Clinic, Rochester, Minnesota, USA.
S G LeckbandVeterans Affairs San Diego Healthcare System, Mental Health Care Line, University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences and Department of Psychiatry, San Diego, California, USA.
J S LeederDivision of Clinical Pharmacology, Toxicology & Innovative Therapeutics, Children's Mercy Hospital, Kansas City, Missouri and Department of Pediatrics, University of Missouri-Kansas City, Kansas City, Missouri, USA.
R L GrahamPhiladelphia Veterans Affairs Medical Center, Philadelphia, Pennsylvania, USA.
D L ChiulliVeterans Affairs Palo Alto Health Care System, San Jose Division, San Jose, California, USA.
A LLerenaCICAB Clinical Research Center, Extremadura University Hospital and Medical School, Badajoz, Spain.
T C SkaarDivision of Clinical Pharmacology, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
S A ScottDepartment of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
J C StinglFederal Institute of Drugs and Medical Devices, Bonn, Germany.
T E KleinDepartment of Genetics, Stanford University, Stanford, California, USA.
K E CaudleDepartment of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
A GaedigkDivision of Clinical Pharmacology, Toxicology & Innovative Therapeutics, Children's Mercy Hospital, Kansas City, Missouri and Department of Pediatrics, University of Missouri-Kansas City, Kansas City, Missouri, USA.
Clinical Pharmacogenetics Implementation Consortium
Stanford University · USUniversity of Missouri–Kansas City · USCentre for Addiction and Mental Health · CACleveland Clinic · USFederal Institute for Drugs and Medical Devices · DEIcahn School of Medicine at Mount Sinai · USIndiana University School of MedicineMayo Clinic · USSt. Jude Children's Research Hospital · USUniversidad de Extremadura · ESUniversity of Minnesota · USVA San Diego Healthcare System · USVeterans Health Administration · US

Funding

PharmGKB: pharmacogenomics knowledge for precision medicineR24GM061374 · NIGMS · STANFORD UNIVERSITY · PI ALTMAN, RUSS BIAGIO, KLEIN, TERI ELLEN · 2010 to 2018
$25.2M
Pharmacogenomics of Anti-platlet Intervention-2 (PAPI-2) StudyU01HL105198 · NHLBI · UNIVERSITY OF MARYLAND BALTIMORE · PI SHULDINER, ALAN R. · 2010 to 2014
$13.6M
PAARK4Kids-Pharmacogenomics of Anticancer Agents Research in ChildrenU01GM092666 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI RELLING, MARY V · 2010 to 2014
$8.9M
Regulation of drug metabolizing enzymes by miRNAsR01GM088076 · NIGMS · INDIANA UNIVERSITY INDIANAPOLIS · PI SKAAR, TODD C. · 2009 to 2017
$3.8M
Clinical Pharmacogenetics Implementation Consortium (CPIC)R24GM115264 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI KLEIN, TERI ELLEN, RELLING, MARY V · 2015 to 2017
$3.6M
Schizophrenia Pharmacogenetics: cognition and symptom response to antipsychoticsK08MH083888 · NIMH · UNIVERSITY OF ILLINOIS AT CHICAGO · PI BISHOP, JEFFREY R · 2009 to 2013
$899k
The Pharmacogenomic Control of Clopidogrel Response in Acute Coronary SyndromesK23GM104401 · NIGMS · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI SCOTT, STUART ALEXANDER · 2013 to 2016
$778k
NHLBI NIH HHS U01 HL0105198NHLBI NIH HHS U01 HL105198NIGMS NIH HHS 2R01GM088076NIGMS NIH HHS K23 GM104401NIGMS NIH HHS K23GM104401NIGMS NIH HHS R01 GM088076NIGMS NIH HHS R24 GM061374NIGMS NIH HHS R24 GM115264NIGMS NIH HHS R24 GM61374NIGMS NIH HHS U01 GM092666NIGMS NIH HHS U01 GM92666NIMH NIH HHS K08 MH083888NIMH NIH HHS K08MH083888
6 · The paper itself

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are primary treatment options for major depressive and anxiety disorders. CYP2D6 and CYP2C19 polymorphisms can influence the metabolism of SSRIs, thereby affecting drug efficacy and safety. We summarize evidence from the published literature supporting these associations and provide dosing recommendations for fluvoxamine, paroxetine, citalopram, escitalopram, and sertraline based on CYP2D6 and/or CYP2C19 genotype (updates at www.pharmgkb.org).

Indexed as

Drug Dosage CalculationsPolymorphism, GeneticBiotransformationCytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6GenotypeHumansPatient SafetyPharmacogeneticsPhenotypeRisk AssessmentRisk FactorsSelective Serotonin Reuptake InhibitorsCYP2C19 protein, humanCytochrome P-450 CYP2C19Cytochrome P-450 CYP2D6Selective Serotonin Reuptake Inhibitors

Identifiers

PMID25974703
PMCPMC4512908
OpenAlexW2161620765

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.